<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The fibroblast growth factor receptor (FGFR) family consists of four members, named FGFR1, 2, 3, and 4 </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 4 FGFRs and their ligands, fibroblast growth factors (FGFs), are expressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies have shown that FGFR2 plays important roles in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e>; therefore, it is of great interest as a novel target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Expression of FGFR2 regulates migration, invasion, and growth in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of the FGFR2 isoform FGFR2 IIIb was associated with well-differentiated histological types, and its specific ligand, FGF7, <z:mp ids='MP_0005601'>enhanced angiogenesis</z:mp> and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to type-IV collagen via FGFR2 IIIb in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>FGFR2 IIIc is detected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, but its roles have not been well elucidated </plain></SENT>
<SENT sid="6" pm="."><plain>Interactions between FGFR2 IIIb and IIIc and FGFs may play important roles in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> via autocrine and/or paracrine signaling </plain></SENT>
<SENT sid="7" pm="."><plain>Several kinds of molecular-targeting agents against FGFR2 have been developed; however, it is not clear how a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment can most effectively inhibit FGFR2 IIIb or FGFR2 IIIc, or both isoforms </plain></SENT>
<SENT sid="8" pm="."><plain>The aim of this paper is to summarize the roles of FGFR2 and its isoforms in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and clarify whether they are potent therapeutic targets for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>